Previous 10 | Next 10 |
Image Sensing Systems (ISNS) +24% on strategic changes.Motus GI Holdings (MOTS) +47% on FDA 510(k) clearance of Pure-Vu System.Tarena International (TEDU) +10% after entering "going private" merger agreement.Salem Media Group (SALM) +9%.Arcutis Biotherapeutics (ARQT) +8%.Mesobl...
Mesoblast (MESO) announces the 60 day results from remestemcel-L trial in 222 ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome ((ARDS)).Remestemcel-L reduced mortality through day 60 by 46% in the pre-specified group below age 65, but not in pati...
NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline of late-stage product candidates, and an activity report for the third quarter ended Marc...
Remestemcel-L reduced mortality through 60 days in the pre-specified population under 65 years old In these patients the benefit was further increased when remestemcel-L was used with dexamethasone as part of standard of care Mortality reduction by remestemcel-L was accompanied by...
InspireMD (NSPR) -19%.Reviva Pharmaceuticals (RVPH) -17%.RealNetworks RNWK -16% on preliminary estimates for its first-quarter, stock offering.Mechanical Technology (MKTY) -10% after subsidiary announces newest addition of the PBS-4100+ portable vibration and balancing system.S...
Maxim analyst Jason McCarthy has upgraded shares of Mesoblast (MESO) from hold to buy and set a price target of $18 as a recent pullback provides an attractive entry point.Remestemcel-L missed its primary endpoints in a trial for chronic lower back pain, COV...
NEW YORK, March 30, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Company’s recent operational highlights, as well as upcoming milestones. Operationa...
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Philip J. Facchina has joined its Board of Directors. Mr Facchina is Chief Strategy Officer of SurgCenter Dev...
BioCardia has a leading-edge cardiac cell therapy platform. The company recently announced a settlement Term Sheet with Boston Scientific, BSX. They are funded through Q3 2022. 29% Inside Ownership. For further details see: BioCardia Is Super Cheap With Multiple Shot...
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion and settlement of its US$110 million private placement led by a strategic US investor gr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...